Last Updated on October 14, 2024 by The Health Master
Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg, to market a generic equivalent of Briviact tablets, 10 mg, 25 mg, 50 mg, 75 mg and 100 mg, of UCB Inc.
The product will be manufactured at Lupin’s Nagpur facility in India, Lupin said in a statement.
It notified that Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older.
“Brivaracetam tablets had estimated annual sales of $311 million in the US (IQVIA MAT June 2021),” it added.
Zydus Cadila gets USFDA nod for Mesalamine ER capsules
Cipla gets USFDA nod for generic Difluprednate Ophthalmic Emulsion
Alembic gets USFDA nod for Clomipramine HCL Capsules
Zydus Cadila gets final nod from USFDA for Fulvestrant injection
USFDA inspection ends with ‘Zero’ observations: Alkem
Granules Pharma clears USFDA audit
Latest Notifications regarding Pharmaceuticals
India and Pharmacy Education: Chapter: 5
Drug unit busted, NDPS drugs seized, 5 arrested
New drug discovered which corrects diet-induced obesity: Research
Govt removes DPCO 2013’s this clause on ceiling price revision
42 FDA Officers honoured on 15th August 2021: Independence Day
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
